

ASX Release

Appendix 4C – Q4 FY 2017 Quarterly Cash Flow Report

30 January 2018 – Sydney, Australia and Dublin, Ireland – Oneview Healthcare PLC (ASX:ONE) today released its Appendix 4C – Quarterly Cashflow report for the period ending 31 December 2017.

Financial Highlights

On 7 December 2017, Oneview announced the successful completion of its underwritten institutional placement and a 1 for 4.35 pro-rata accelerated non-renounceable entitlement offer. The placement and entitlement offer raised approximately €19.19 million (equivalent to A\$30.0 million) for the Company through the issue of 15,005,523 new securities at the offer price of A\$2.00 per new CDI. Transaction costs related to the raise amounted to €1.39 million.

Operating cash outflows for the quarter were approximately €5.48 million which included

- Receipts from customers of €2.59 million, up from €0.66 million the previous quarter (+290%). Full year cash receipts amount to €7.35 million;
- Payments for staff costs in the quarter amounted to €5.03 million, inclusive of US restructuring costs, which compares to €4.63 million in the prior quarter. Full year costs amounted to €19.59 million.
- Direct costs incurred for hardware and implementation amounted to €1.56 million (€2.76 million for the full year), while administration and corporate costs were €1.50 million inclusive of unrealised foreign exchange movements.

The Company continues to be committed to managing cash outflows and controlling costs. Cash balances as at 31 December amounted to €28.61 million.

Operational Highlights

The Company recently announced the signing of a number of new commercial agreements including:-

- Mater Misericordiae Limited, a network of hospitals and healthcare facilities throughout Brisbane, Redland and Springfield, Australia, to deploy the Oneview patient engagement and clinical workflow solution in 904 beds across 9 facilities;
- UCSF Benioff Children's Hospital Oakland, California to deploy over 300 interactive bedside touchscreen devices and interactive patient television locations for patients and their families across the hospitals existing outpatient centre, a new outpatient building currently under construction, and the UCSF Benioff Oakland hospital and UCSF Benioff inpatient unit at Summit Medical Centre. The agreement follows the deployment of the Oneview solution at UCSF Health's Mission Bay campus which went live in February 2015 in both the paediatric and adult hospitals. The Oneview solution will provide an immersive experience for patients and their families, including a digital whiteboard, education assignment with automatic EHR writeback, digital meal ordering, interactive television, movies on demand. Streaming services and games.
- Chris O'Brien Lifehouse, a not-for-profit cancer treatment centre in Sydney, Australia with a new six year contract extension and expansion.
- Oxford University and Oxford University Hospitals NHS Foundation Trust with a 5 year Research and Development Agreement to develop clinical pathways aimed at easing administrative burden, digitising current paper based processes and ultimately expediting cancer waiting times and access to care. This follows the success a Prostate Cancer Pathways pilot project with Oxford University Hospital. The new Research and Development Agreement will focus on expanding the technology to include full commercial deployment at Oxford via a

SMART on FHIR integration and expansion of scope to other types of cancer (lung, breast, oesophageal etc). The partners expect to commercialise the new products globally, connecting information across systems to drive clinical transformation and reduce variation.

About Oneview Healthcare

Oneview provides interactive healthcare technologies for patients, families and caregivers. Oneview's technology weaves a facility's existing disparate systems into a single seamless platform, allowing healthcare facilities to engage patients in meaningful ways, improve communication, and streamline clinical workflows. Patients enjoy the comfort and convenience of information, education, entertainment and environmental controls at the bedside, while facilities enjoy better health outcomes and staff satisfaction.

Enquiries: James Fitter

Oneview Healthcare

Website : www.oneviewhealthcare.com

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")

31st December 2017

Consolidated statement of cash flows	Current quarter €'000	Year to date (12 months) €'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,590	7,352
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(1,560)	(2,760)
(c) advertising and marketing	(99)	(776)
(d) leased assets	-	-
(e) staff costs	(5,029)	(19,589)
(f) administration and corporate costs	(1,498)	(7,211)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	(91)
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material) – incl. general working capital movements.	117	1,242
1.9 Net cash from / (used in) operating activities	(5,479)	(21,833)

Consolidated statement of cash flows		Current quarter €'000	Year to date (12 months) €'000
2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(165)	(1,233)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(165)	(1,233)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	19,189	19,189
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	4	19
3.4	Transaction costs related to issues of shares, convertible notes or options	(1,394)	(1,394)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	17,799	17,814

Consolidated statement of cash flows		Current quarter €'000	Year to date (12 months) €'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	15,810	35,088
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(5,479)	(21,833)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(165)	(1,233)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	17,799	17,814
4.5	Effect of movement in exchange rates on cash held	646	(1,225)
4.6	Cash and cash equivalents at end of quarter	28,611	28,611

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	28,611	28,611
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	28,611	28,611

6.	Payments to directors of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to these parties included in item 1.2	289
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

7. Payments to related entities of the entity and their associates	Current quarter €'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		


9. Estimated cash outflows for next quarter	€'000
9.1 Research and development	-
9.2 Product manufacturing and operating costs	(1,765)
9.3 Advertising and marketing	(223)
9.4 Leased assets	-
9.5 Staff costs	(4,849)
9.6 Administration and corporate costs	(1,685)
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	(8,522)

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	-	-
10.2	Place of incorporation or registration	-	-
10.3	Consideration for acquisition or disposal	-	-
10.4	Total net assets	-	-
10.5	Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:



 (Director)

Date: 30 January 2018

Print name: John Kelly

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.